{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95 %Cl was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"4.17","upperLimit":"NA","value":"5.62"},{"comment":"Upper limit of 95 %Cl was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"5.52","upperLimit":"NA","value":"9.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by IRF assessment using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \\<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received. Overall number analyzed is the number of participants with response, per IRF.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Randomized Phase: Duration of Response (DOR) as Determined by the IRF","type":"SECONDARY","unitOfMeasure":"months"}